A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess Sleep, Health Outcomes, and Overall Well-Being in Healthy Adults Reporting Disturbed Sleep, Taking a Melatonin-Free Supplement.
Kolobaric et al.·NutrientsImpact 5.4
Klarer NutzenGRADEHoch15 Zitate
Stichproben = 620 Pat.
Dauer4 weeks
KontrollePlacebo
EndpunktPROMIS Sleep Disturbance SF 8A
Verblindungdoppelblind
DesignRCT
Cannabinoidthc
Max. Dosis0.85 mg
Applikationoral
”Kernaussage
Sleep A (niedrige THC + hohe Botanicals) zeigte signifikante Verbesserungen bei Schlafstörung, Angst, Stress und Wohlbefinden im Vergleich zu Placebo; Sleep B zeigte keine signifikanten Unterschiede.
Zusammenfassung
n=620 Erwachsene mit Schlafstörungen, 3-armige RCT über 4 Wochen. Sleep A (0.35 mg THC + 75 mg Hopfen/Baldrian) vs. Sleep B (0.85 mg THC + 20 mg Hopfen/Baldrian) vs. Placebo. Sleep A zeigte signifikante Verbesserung der PROMIS Sleep Disturbance gegenüber Placebo (p<0.05, exakter Wert nicht angegeben); zusätzlich Reduktion von Angst, Stress und Verbesserung des Wohlbefindens. Sleep B zeigte keine signifikanten Unterschiede zu Placebo. Nebenwirkungen mild bis moderat, keine Gruppenunterschiede.
P
PopulationGesunde Erwachsene mit Schlafstörungen, n=620
OutcomeSignifikante Verbesserung der Schlafstörung, Angst, Stress und Wohlbefinden für Sleep A vs. Placebo; kein signifikanter Unterschied für Sleep B vs. Placebo
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Qualitätsprofil
Größe★★★★★
VerblindungDoppelblind
EffektstärkeKlarer Nutzen
Zitate / Jahr★★★★★
Autoren
Kolobaric A, Hewlings SJ, Bryant C, Colwell CS, R D'Adamo C, Rosner B, Chen J, Pauli EK
Inadequate sleep is a global health concern. Sleep is multidimensional and complex; new multi-ingredient agents are needed. This study assessed the comparative effects of two multi-ingredient supplements on sleep relative to placebo. Adults (N = 620) seeking better sleep were randomly assigned to receive one of three study products. Sleep A (contained lower (0.35 mg THC and higher levels of botanicals (75 mg each hops oil and valerian oil), Sleep B (contained higher THC (0.85 mg) and lower botanicals (20 mg each hops oil and valerian oil) or placebo) for 4 weeks. Sleep disturbance was assessed at baseline and weekly using NIH's Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance SF 8A survey. Anxiety, stress, pain, and well-being were assessed using validated measures at baseline and weekly. A linear mixed-effects regression model was used to assess the change in health outcome score between active product groups and the placebo. There was a significant difference in sleep disturbance, anxiety, stress, and well-being between Sleep A and placebo. There was no significant difference in any health parameter between Sleep B and placebo. Side effects were mild or moderate. There were no significant differences in the frequency of side effects between the study groups. A botanical blend containing a low concentration of THC improved sleep disturbance, anxiety, stress, and well-being in healthy individuals that reported better sleep as a primary health concern.